Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCTs031180445
JPRN-jRCTs031180445Active, not recruitingPhase 2

Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin (GDP) for Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma - NHOH-PTCL-GDPR

IWASAKI Hiromi0 sites30 target enrollmentStarted: March 29, 2019Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Active, not recruiting
Sponsor
Enrollment
30
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 65age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • •1) The patient is 65 years old or older at the time of registration.
  • •2) The patient is diagnosed with peripheral T-cell lymphoma (PTCL-NOS or AITL according to the 2016 WHO classification), has previously undergone more than one treatment regimen, are not eligible for autologous and allogeneic stem-cell transplantation, and their condition has relapsed or is refractory.
  • •3) The patient has a lesion that is measurable.
  • •4) The patient's Eastern Cooperative Oncology Group Performance Status at the time of registration is 0-2.
  • •This can be after a previous PSL dose (approx. one-week PSL administration is permissible).
  • •5) The patient satisfies the following criteria and the major organ functions have been maintained.
  • •5-a) The patient has a neutrophil count of 1,000/mm^3L and above.
  • •5-b) The patient has a platelet count of 50,000/mm^3L and above.
  • •5-c) The patient's cardiac function has an ejection fraction of over 50% (echocardiogram or myocardial scintigraphy).
  • •5-d) The patient's arterial blood gas analysis shows a PaO2 of over 60 mmHg, or the percutaneous oxygen saturation measurement shows an SpO2 of over 93% (room air).
  • •5-E) The patient's serum AST or ATL is less than 5 times the maximum value of the facility standard.
  • •5-F) The patient's creatinine clearance is over 30 ml/min (Cockcroft-Gault).
  • •6) The patient has received a notification and the content of the trial has been adequately explained to the patient by the facility investigator (assigned) using the designated consent form and explanatory materials, and the patient has provided written informed consent of voluntary participation in the trial.

Exclusion Criteria

  • •1) The patient has been clinically diagnosed with testis or central nervous system (brain, spinal cord, medullary cavity).
  • •(An examination of the cerebrospinal fluid or an MRI of the brain is not mandatory)
  • •2) The patient has uncontrolled hepatic, renal, cardiac, or pulmonary dysfunction, diabetes, or hypertension.
  • •3) The patient has interstitial pneumonia or pulmonary fibrosis. (If either is determined by a plain X-ray image of the chest, the patient shall not be able to register. Mild cases indicated for the first time on a chest CT scan shall not be excluded. Patients whose lungs have been previously exposed to radiation shall be excluded, as they are at a high risk of developing interstitial pneumonia.)
  • •4) The patient presents with a QTc interval that measures over 500 ms on an electrocardiogram.
  • •5) The patient has a tubercular disease, herpetic simplex keratitis, systemic mycoses, or any other active infection.
  • •6) The patient has had, within the past 6 months, an acute myocardial infarction, deep vein thrombosis, or a pulmonary embolism.
  • •7) The patient has an active and advanced stage double cancer (synchronous double cancer and metachronous double cancer with a disease-free interval of less than 5 years. However, lesions that correspond to carcinoma in situ of the uterine cervix, the stomach, or the colon that are deemed to have been cured by local treatment are not considered as active double cancers).
  • •8) The patient is HBs antigen positive, HCV antigen positive, HTLV-1 antigen positive, or HIV antigen positive. (HBs antibody and HBc antibody positive patients shall not be excluded. If HBV-DNA is detected, the patient shall be excluded. An HIV antibody test is not mandatory).
  • •9) The patient has a history of severe drug hypersensitivity.
  • •10) The patient lacks the ability to give consent, suffering from symptoms such as dementia.
  • •11) The patient has undergone local radiotherapy less than 2 weeks prior to the trial.
  • •12) The representative doctor of the facility or investigator deems the patient to be unfit to participate in the trial.

Investigators

Sponsor
IWASAKI Hiromi

Similar Trials

Terminated
Phase 1
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerHER2-negative Breast CancerRecurrent Breast CancerMale Breast CancerStage IV Breast CancerInflammatory Breast Cancer
NCT01938833Sidney Kimmel Cancer Center at Thomas Jefferson University9
Completed
Phase 1
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell LymphomaPeripheral T-Cell LymphomaDiffuse Large B-Cell Lymphoma
NCT01846390Canadian Cancer Trials Group21
Active, not recruiting
Phase 1
Phase IIa study on the role of Gemcitabine plus Romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Relapsed/refractory peripheral T-cell lymphoma patients.MedDRA version: 14.1Level: HLGTClassification code 10025321Term: Lymphomas non-Hodgkin's T-cellSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2012-001404-38-ITFONDAZIONE ITALIANA LINFOMI ONLUS20
Completed
Phase 2
Romidepsin Plus 3BNC117 Phase 2a StudyHuman Immunodeficiency Virus (HIV)
NCT02850016Rockefeller University48
Completed
Phase 2
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell LymphomaPeripheral T-cell Lymphoma
NCT00426764Celgene131